CDK9 inhibitor A09-003 overcomes TRAIL resistance via dual Mcl-1 suppression in breast cancer cells
Abstract Background Resistance to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a main limitation in breast cancer therapy. Identifying effective sensitizers is crucial to overcome this hurdle. Cyclin-dependent kinase-9 (CDK-9) inhibition has recently emerged as a potential stra...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer
2026-05-01
|
| Col·lecció: | Discover Oncology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1007/s12672-026-04958-6 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|